HSE - PCRS

Application Details

HSE Application ID

HSE100094

HTA Number

26009

HTA Link

https://www.ncpe.ie/tislelizumab-tevimbra-nsq-nsclc-hta-id-26009/

Drug

tislelizumab

Brand

Tevimbra®

Applicant

BeOne Medicines Ireland Limited

Indication Applied For

Tislelizumab in combination with pemetrexed and platinum-containing chemotherapy indicated for the first-line treatment of adult patients with non-squamous non-small cell lung cancer (NSCLC) whose tumours have PD-L1 expression on ≥50% of tumour cells with no EGFR or ALK positive mutations and who have:
• locally advanced non-small cell lung cancer (NSCLC) and are not candidates for surgical resection or platinum-based chemoradiation, or
• metastatic non-small cell lung cancer (NSCLC).

Application Date

17/03/2026

Marketing Authorisation Date

08/07/2024

Application Status

Awaiting Proposal from Applicant

28/05/2026

Applicant Meeting Held with CPU

28/05/2026

Rapid Review Completed

10/04/2026

Pricing and Reimbursement Application Complete

17/03/2026

Rapid Review Commissioned

11/03/2026

New Search